For example, several case studies have shown that exon 19 deletions and exon 21 substitutions such as L858R, which account for approximately 50% of EGFR mutations in NSCLC, are known sensitizers to first and second generation TKIs [94,95,96,97]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.